New Drug Investment Return Down 12% Since Waxman/Hatch - CBO Report
The commercial return from marketing a new drug has declined by 12% since the Waxman/Hatch Act was enacted in 1984, the Congressional Budget Office estimates in a July report.
The commercial return from marketing a new drug has declined by 12% since the Waxman/Hatch Act was enacted in 1984, the Congressional Budget Office estimates in a July report.